DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics today announced the presentation of two abstracts related to its personalized dendritic cell-based immunotherapy programs at the 22nd Annual Meeting of the International Society for the Biological Treatment of Cancer (iSTBc), held November 2-4 in Boston. Results from the presented abstracts reveal that Argos’ immunotherapeutic candidate AGS-003 is compatible in combination with sunitinib (Sutent®) for the treatment of renal cell carcinoma (RCC). Argos researchers also will present pre-clinical data demonstrating that the Company’s proprietary process for the optimization of dendritic cells, called Arcelis, is capable of inducing a strong and robust immune response appropriate for the treatment of cancer, and that this approach may be superior to other currently used processes.
